<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content=
"text/html; charset=utf-8" /><!-- AppResources meta begin -->

<script type="text/javascript">
//<![CDATA[
var ncbi_startTime = new Date();
//]]>
</script><!-- AppResources meta end -->
<!-- TemplateResources meta begin -->
<meta name="paf_template" content="" />
<!-- TemplateResources meta end -->
<!-- Logger begin -->
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_pdid" content="article" />
<meta name="ncbi_acc" content="" />
<meta name="ncbi_domain" content="nihpa" />
<meta name="ncbi_report" content="record" />
<meta name="ncbi_type" content="fulltext" />
<meta name="ncbi_objectid" content="" />
<meta name="ncbi_pcid" content="/articles/PMC1865122/" />
<meta name="ncbi_app" content="pmc" /><!-- Logger end -->
<title>Assessing the clinical significance of botanical
supplementation on human cytochrome P450 3A activity: Comparison of
a milk thistle and black cohosh product to rifampin and
clarithromycin</title>
<!-- AppResources external_resources begin -->
<link rel="stylesheet" href="/core/jig/1.14.4/css/jig.min.css" />
<script type="text/javascript" src=
"/core/jig/1.14.4/js/jig.min.js">
</script><!-- AppResources external_resources end -->
<!-- Page meta begin -->
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" />
<link rel="canonical" href="/pmc/articles/PMC1865122/" />
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" />
<meta name="citation_journal_title" content=
"Journal of clinical pharmacology" />
<meta name="citation_title" content=
"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin" />
<meta name="citation_authors" content=
"Bill Gurley, Martha A. Hubbard, D. Keith Williams, John Thaden, Yudong Tong, W. Brooks Gentry, Philip Breen, Danielle J. Carrier, Shreekar Cheboyina" />
<meta name="citation_date" content="February 2006" />
<meta name="citation_issue" content="2" />
<meta name="citation_volume" content="46" />
<meta name="citation_firstpage" content="201" />
<meta name="citation_doi" content="10.1177/0091270005284854" />
<meta name="citation_abstract_html_url" content=
"/pmc/articles/PMC1865122/?report=abstract" />
<meta name="citation_pmid" content="16432272" />
<meta name="DC.Title" content=
"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin" />
<meta name="DC.Type" content="Text" />
<meta name="DC.Publisher" content="NIH Public Access" />
<meta name="DC.Contributor" content="Bill Gurley" />
<meta name="DC.Contributor" content="Martha A. Hubbard" />
<meta name="DC.Contributor" content="D. Keith Williams" />
<meta name="DC.Contributor" content="John Thaden" />
<meta name="DC.Contributor" content="Yudong Tong" />
<meta name="DC.Contributor" content="W. Brooks Gentry" />
<meta name="DC.Contributor" content="Philip Breen" />
<meta name="DC.Contributor" content="Danielle J. Carrier" />
<meta name="DC.Contributor" content="Shreekar Cheboyina" />
<meta name="DC.Date" content="2006 Feb" />
<meta name="DC.Identifier" content="10.1177/0091270005284854" />
<meta name="DC.Language" content="en" />
<meta property="og:title" content=
"Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin" />
<meta property="og:type" content="article" />
<meta property="og:description" content=
"Phytochemical-mediated modulation of cytochrome P450 enzymes (CYPs) may underlie many herb-drug interactions. This study’s purpose was to assess the effects of milk thistle and black cohosh supplementation on CYP3A activity and compare them to ..." />
<meta property="og:url" content=
"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1865122/" />
<meta property="og:site_name" content="PubMed Central (PMC)" />
<meta property="og:image" content=
"http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" />
<meta name="twitter:card" content="summary" />
<meta name="twitter:site" content="@ncbi" />
<link rel="stylesheet" href="/corehtml/pmc/css/3.4/pmc.min.css"
type="text/css" />
<link rel="stylesheet" href=
"/corehtml/pmc/css/3.4/pmc_extras_prnt.min.css" type="text/css"
media="print" />
<script type="text/javascript" src=
"/corehtml/pmc/js/common.min.js">
//<![CDATA[
//
//]]>
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/NcbiTagServer.min.js">
//<![CDATA[
//
//]]>
</script>
<meta name="citationexporter" content=
"backend:'/pmc/utils/ctxp/'" />
<script type="text/javascript" src=
"/corehtml/pmc/ctxp/jquery.citationexporter.js">
//<![CDATA[
//
//]]>
</script>
<link rel="stylesheet" href=
"/corehtml/pmc/ctxp/citationexporter.css" type="text/css" />
<script type="text/javascript" src=
"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js">
</script>
<script type="text/javascript" src=
"/corehtml/pmc/js/large-obj-scrollbars.min.js">
</script>
<script type="text/javascript">
//<![CDATA[
window.name="mainwindow";
//]]>
</script>
<style type="text/css">
/*<![CDATA[*/
.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
.print-view{display:block}
/*]]>*/
</style>

<style type="text/css">
/*<![CDATA[*/
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
/*]]>*/
</style>
<link rel="alternate" type="application/epub+zip" href=
"/pmc/articles/PMC1865122/epub/" />
<link rel="alternate" type="application/pdf" href=
"/pmc/articles/PMC1865122/pdf/nihms20441.pdf" />
<!-- Page meta end -->
<link rel="shortcut icon" href=
"//www.ncbi.nlm.nih.gov/favicon.ico" />
<meta name="ncbi_phid" content=
"8A1A16CC6FE7C4410000000000D8DED2" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3852956/3985586/3808861/3734262/3974050/3917732/251717/4048120/3846471/14534/45193/3988413/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css" />
<link type="text/css" rel="stylesheet" href=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/css/3411343/3882866/3929378.css"
media="print" />
</head>
<body class="article">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
<div class="sysmessages"><noscript>
<p class="nojs"><strong>Warning:</strong> The NCBI web site
requires JavaScript to function. <a href=
"/guide/browsers/#enablejs" title="Learn how to enable JavaScript"
target="_blank">more...</a></p>
</noscript></div>
<!--/.sysmessage-->
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id=
"navcontent">
<li class=
"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt">
<a class="ui-ncbimenu-link-first" href="/" role="banner" title=
"NCBI Home" id="ncbihome" accesskey="1"><span class=
"offscreen_noflow">NCBI</span><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/28977"
class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#maincontent" title="Skip to the content" tabindex="0" accesskey=
"3">Skip to main content</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"#navcontent" title="Skip to the navigation" tabindex="0"
accesskey="4">Skip to navigation</a></li>
<li id="resource-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset">
<a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href=
"/static/header_footer_ajax/submenu/#resources">Resources</a></li>
<li id="all-howtos-menu" class=
"topmenu ui-helper-reset ui-ncbimenu-item-first"><a class=
"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown"
href="/static/header_footer_ajax/submenu/#howto">How To</a></li>
<li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href=
"/guide/browsers/#accesskeys" title="About My NCBI Accesskeys"
tabindex="0" accesskey="0">About NCBI Accesskeys</a></li>
</ul>
<div class="myncbi"><span id="myncbiusername" style=
"display:none"><a href="/account/settings/" id="mnu" title=
"Edit account settings"></a></span><a accesskey="2" href="/myncbi/"
id="myncbi" style="display:none">My NCBI</a><a href="/account/" id=
"sign_in">Sign in to NCBI</a><a href="/account/signout/" id=
"sign_out" style="display:none">Sign Out</a></div>
</div>
<div class="header">
<div class="res_logo">
<h1 class="img_logo"><a href="/pmc/" class=
"pmc_logo offscreen">PMC</a></h1>
<div class="NLMLogo"><a href="http://www.nlm.nih.gov/" title=
"US National Library of Medicine">US National Library of
Medicine</a><br />
<a href="http://www.nih.gov/" title=
"National Institutes of Health">National Institutes of
Health</a></div>
</div>
<div class="search">
<form method="get" action="/pmc/">
<div class="search_form"><label for="database" class=
"offscreen_noflow">Search database</label><select id="database">
<optgroup label="Recent">
<option value="pmc" selected="selected" class="last" data-ac_dict=
"pmc-search-autocomplete">PMC</option>
</optgroup>
<optgroup label="All">
<option value="gquery">All Databases</option>
<option value="assembly">Assembly</option>
<option value="bioproject">BioProject</option>
<option value="biosample">BioSample</option>
<option value="biosystems">BioSystems</option>
<option value="books">Books</option>
<option value="clinvar">ClinVar</option>
<option value="clone">Clone</option>
<option value="cdd">Conserved Domains</option>
<option value="gap">dbGaP</option>
<option value="dbvar">dbVar</option>
<option value="epigenomics">Epigenomics</option>
<option value="nucest">EST</option>
<option value="gene">Gene</option>
<option value="genome">Genome</option>
<option value="gds">GEO DataSets</option>
<option value="geoprofiles">GEO Profiles</option>
<option value="nucgss">GSS</option>
<option value="gtr">GTR</option>
<option value="homologene">HomoloGene</option>
<option value="medgen">MedGen</option>
<option value="mesh">MeSH</option>
<option value="ncbisearch">NCBI Web Site</option>
<option value="nlmcatalog">NLM Catalog</option>
<option value="nuccore">Nucleotide</option>
<option value="omim">OMIM</option>
<option value="pmc" data-ac_dict="pmc-search-autocomplete">
PMC</option>
<option value="popset">PopSet</option>
<option value="probe">Probe</option>
<option value="protein">Protein</option>
<option value="proteinclusters">Protein Clusters</option>
<option value="pcassay">PubChem BioAssay</option>
<option value="pccompound">PubChem Compound</option>
<option value="pcsubstance">PubChem Substance</option>
<option value="pubmed">PubMed</option>
<option value="pubmedhealth">PubMed Health</option>
<option value="snp">SNP</option>
<option value="sra">SRA</option>
<option value="structure">Structure</option>
<option value="taxonomy">Taxonomy</option>
<option value="toolkit">ToolKit</option>
<option value="toolkitall">ToolKitAll</option>
<option value="toolkitbook">ToolKitBook</option>
<option value="toolkitbookgh">ToolKitBookgh</option>
<option value="unigene">UniGene</option>
</optgroup>
</select>
<div class="nowrap"><label for="term" class="offscreen_noflow"
accesskey="/">Search term</label>
<div class="nowrap"><input type="text" name="term" id="term" title=
"Search PMC. Use up and down arrows to choose an item from the autocomplete."
value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config=
"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'"
autocomplete="off" data-sbconfig=
"ds:'no',pjs:'no',afs:'yes'" /></div>
<button id="search" type="submit" class="button_search nowrap" cmd=
"go">Search</button></div>
</div>
</form>
<ul class="searchlinks inline_list">
<li><a href="/pmc/limits/">Limits</a></li>
<li><a href="/pmc/advanced/">Advanced</a></li>
<li><a href="/pmc/journals/">Journal list</a></li>
<li class="help"><a target="_blank" href=
"/books/NBK3825/">Help</a></li>
</ul>
</div>
</div>
<!--<component id="Page" label="headcontent"/>--></div>
<div class="content"><!-- site messages -->
<div class="container">
<div id="maincontent" class="content eight_col col">
<div class="navlink-box">
<ul class="page-breadcrumbs inline_list small">
<li class="journal-list"><a href="/pmc/journals/" class=
"navlink">Journal List</a></li>
<li class="article-entrez-filter"><a href=
"/pmc/?term=hhs%20author%20manuscript[filter]&amp;sort=SortDate&amp;cmd=search&amp;EntrezSystem2.PEntrez.Pmc.Pmc_LimitsTab.LimitsOff=true"
class="navlink">HHS Author Manuscripts</a></li>
<li class="accid">PMC1865122</li>
</ul>
</div>
<!-- Journal banner -->
<div class="pmc-page-banner whole_rhythm">
<div><img src="/corehtml/pmc/pmcgifs/logo-hhspa.png" alt=
"Logo of nihpa" usemap="#logo-imagemap" /><map id="logo-imagemap"
name="logo-imagemap">
<area shape="rect" coords="0,57,255,75" alt=
"About Author manuscripts" title="About Author manuscripts" href=
"http://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" ref=
"http://www.ncbi.nlm.nih.gov/pmc/about/authorms.html" />
<area shape="rect" coords="256,57,500,75" alt="Submit a manuscript"
title="Submit a manuscript" href="http://www.nihms.nih.gov/" ref=
"reftype=publisher&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"
target="pmc_ext" />
<area shape="rect" coords="0,0,499,74" alt=
"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;"
title=
"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;"
href="http://www.ncbi.nlm.nih.gov/pmc/about/public-access/" ref=
"reftype=publisher&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"
target="pmc_ext" /></map></div>
</div>
<!--component id='MainPortlet' label='search-reference'/-->
<!-- Book content -->
<div class="">
<div class=
"hide-overflow article lit-style content pmc-wm slang-all page-box">
<!--main-content-->
<div class="jig-ncbiinpagenav" data-jigconfig=
"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'">
<div class="fm-sec half_rhythm no_top_margin">
<div class="fm-citation half_rhythm no_top_margin clearfix">
<div class="small">
<div class="inline_block eight_col va_top">
<div>J Clin Pharmacol. Author manuscript; available in PMC 2007 May
3.</div>
<div>Published in final edited form as:</div>
<div style="margin-left:1em">
<div class="fm-vol-iss-date"><a href=
"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=16432272"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal">
<span class="cit">J Clin Pharmacol. 2006 Feb; 46(2):
201–213.</span></a></div>
<span class="doi">doi:&nbsp; <a href=
"http://dx.doi.org/10.1177%2F0091270005284854" target="pmc_ext"
ref="reftype=other&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">
10.1177/0091270005284854</a></span></div>
</div>
<div class=
"inline_block four_col va_top show-overflow align_right">
<div class="fm-citation-ids">
<div class="fm-citation-pmcid"><span class=
"fm-citation-ids-label">PMCID:</span> <span>PMC1865122</span></div>
<div class="fm-citation-manuscriptid"><span class=
"fm-citation-ids-label">NIHMSID:</span>
<span>NIHMS20441</span></div>
</div>
</div>
</div>
</div>
<h1 class="content-title">Assessing the clinical significance of
botanical supplementation on human cytochrome P450 3A activity:
Comparison of a milk thistle and black cohosh product to rifampin
and clarithromycin</h1>
<div class="half_rhythm">
<div class="contrib-group fm-author"><a href=
"/pubmed/?term=Gurley%20B%5Bauth%5D">Bill Gurley</a>, Ph.D.,
<a href="/pubmed/?term=Hubbard%20MA%5Bauth%5D">Martha A.
Hubbard</a>, M.S., <a href=
"/pubmed/?term=Williams%20DK%5Bauth%5D">D. Keith Williams</a>,
Ph.D., <a href="/pubmed/?term=Thaden%20J%5Bauth%5D">John
Thaden</a>, Ph.D., <a href=
"/pubmed/?term=Tong%20Y%5Bauth%5D">Yudong Tong</a>, M.S., <a href=
"/pubmed/?term=Gentry%20WB%5Bauth%5D">W. Brooks Gentry</a>, M.D.,
<a href="/pubmed/?term=Breen%20P%5Bauth%5D">Philip Breen</a>,
Ph.D., <a href="/pubmed/?term=Carrier%20DJ%5Bauth%5D">Danielle J.
Carrier</a>, Ph.D., and <a href=
"/pubmed/?term=Cheboyina%20S%5Bauth%5D">Shreekar Cheboyina</a>,
Ph.D.</div>
</div>
<div class="fm-panel small half_rhythm">
<div class="fm-authors-info fm-panel hide half_rhythm" id=
"id463725_ai" style="display:none">
<div class="fm-affl" lang="en">From the Department of
Pharmaceutical Sciences (Dr. Gurley, Ms. Hubbard, Mr. Tong, and Dr.
Breen), Department of Biostatistics (Dr. Williams), Department of
Anesthesiology (Dr. Gentry), and the Small Molecule Mass
Spectrometry Facility (Dr. Thaden), University of Arkansas for
Medical Sciences, Little Rock, Arkansas; Department of Agricultural
Engineering (Dr. Carrier), University of Arkansas, Fayetteville,
Arkansas; and Department of Pharmaceutics (Dr. Cheboyina),
University of Mississippi, University, Mississippi. Study approved
by the Institutional Review Board of the University of Arkansas for
Medical Sciences. This work was supported by the NIH/NIGMS under
grant RO1 GM71322 and by NIH/NCRR to the General Clinical Research
Center of the University of Arkansas for Medical Sciences under
grant M01 RR14288</div>
<div id="FN1">Address for reprints: Bill J. Gurley, University of
Arkansas for Medical Sciences, College of Pharmacy, Department of
Pharmaceutical Sciences, 4301 W. Markham St., Slot 522-3, Little
Rock, AR 72205; e-mail <a href="mailto:dev@null" data-email=
"ude.smau@jyllibyelrug" class=
"oemail">ude.smau@jyllibyelrug</a></div>
</div>
<div class="togglers"><a href="#" class="pmctoggle" rid=
"id463725_ai">Author information <span>►</span></a> <a href="#"
class="pmctoggle" rid="id463725_cpl">Copyright and License
information <span>►</span></a></div>
<div class="fm-article-notes fm-panel half_rhythm"></div>
<div class="fm-cpl-info fm-panel hide half_rhythm" id=
"id463725_cpl" style="display:none">
<div class="fm-copyright half_rhythm"><a href=
"/pmc/about/copyright.html">Copyright notice</a> and <a href=
"/About/disclaimer.html">Disclaimer</a></div>
</div>
</div>
<div class="links-box fm-panel whole_rhythm">
<div class="small">
<div>The publisher's final edited version of this article is
available at <a href=
"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=16432272"
target="pmc_ext" ref=
"reftype=publisher&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal">
J Clin Pharmacol</a></div>
<div>See other articles in PMC that <a href=
"/pmc/articles/PMC1865122/citedby/">cite</a> the published
article.</div>
</div>
</div>
</div>
<div class="sec"></div>
<div id="__abstractid476322" lang="en" class="tsec sec">
<h2 class="head no_bottom_margin" id="__abstractid476322title">
Abstract</h2>
<!--article-meta-->
<div>
<p id="P1" class="p p-first-last">Phytochemical-mediated modulation
of cytochrome P450 enzymes (CYPs) may underlie many herb-drug
interactions. This study’s purpose was to assess the effects of
milk thistle and black cohosh supplementation on CYP3A activity and
compare them to a clinically recognized inducer, rifampin, and
inhibitor, clarithromycin. Healthy volunteers were randomly
assigned to receive a standardized milk thistle (900 mg) or black
cohosh (80 mg) supplement for 14 days. Subjects also received
rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as
positive controls for CYP3A induction and inhibition, respectively.
Midazolam was administered orally before and after each
supplementation and control period. The effects of milk thistle,
black cohosh, rifampin, and clarithromycin on midazolam
pharmacokinetics were determined using noncompartmental techniques.
Unlike those observed for rifampin and clarithromycin, midazolam
pharmacokinetics were unaffected by milk thistle or black cohosh.
Milk thistle and black cohosh appear to have no clinically relevant
effect on CYP3A activity in vivo.</p>
</div>
<div class="sec"><strong class="kwd-title">Keywords:</strong>
<span class="kwd-text">Cytochrome P450s, botanical supplements,
pharmacokinetics, drug interactions</span></div>
</div>
<div id="__bodyid807989" class="tsec sec headless whole_rhythm">
<p id="P2" class="p p-first">Concomitant self-administration of
botanical supplements with conventional medications is a growing
trend in the United States. Approximately 20% of adults take
prescription medications concurrently with botanical dietary
supplements.<sup><a href="#R1" rid="R1" class=
" bibr popnode">1</a></sup><sup>,</sup><sup><a href="#R2" rid="R2"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211977">2</a></sup> This upsurge in botanical supplement
usage has sparked an increased concern regarding herb-drug
interactions.<sup><a href="#R3" rid="R3" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211930">3</a></sup><sup>,</sup><sup><a href="#R4" rid=
"R4" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211910">4</a></sup> Supplement-derived phytochemicals
appear to modulate various cytochrome P450 enzymes (i.e., CYP3A4)
and drug transporters (i.e., P-glycoprotein [P-gp,) in vitro, and
such activities may underlie many herb-drug interactions. Of the
hundreds of botanical supplements sold in the United States, St.
John’s wort (<em>Hypericum perforatum</em>) is the most noteworthy
for producing clinically significant herb-drug interactions.
Interactions involving St. John’s wort can be traced to hyperforin,
a phytochemical component of <em>H. perforatum</em> and a potent
ligand for the steroid xenobiotic receptor (SXR),<sup><a href="#R5"
rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211940">5</a></sup> which functions as a transcription
factor for the <em>CYP3A4</em> and <em>ABCB1</em> genes. Chronic
ingestion of St. John’s wort leads to up regulation of intestinal
CYP3A4 and P-gp (the gene product of <em>ABCB1</em>) expression, a
consequence of which is pronounced reduction in oral
bioavailability of many conventional medications.<sup><a href="#R6"
rid="R6" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211923">6</a></sup><sup>–</sup><sup><a href="#R8" rid=
"R8" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211922">8</a></sup></p>
<p id="P3">Numerous in vitro studies suggest that other botanical
supplements may be capable of modulating CYP activity;<sup><a href=
"#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311359069">9</a></sup><sup>–</sup><sup><a href="#R11" rid=
"R11" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211979">11</a></sup> however, results from human in vivo
studies have been less compelling. Besides St. John’s wort, only
goldenseal,<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211962">12</a></sup> garlic oil,<sup><a href="#R13" rid=
"R13" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211900">13</a></sup><sup>,</sup><sup><a href="#R14" rid=
"R14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211933">14</a></sup> ginkgo biloba,<sup><a href="#R15"
rid="R15" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211919">15</a></sup> and possibly echinacea,<sup><a href=
"#R16" rid="R16" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211966">16</a></sup> appear capable of significantly
affecting human CYP activity in vivo. Results from clinical studies
into the interaction potential of other popular supplements,
particularly garlic powder and milk thistle, have been equivocal.
Piscitelli et al. observed a significant reduction in saquinavir
area-under-the-curve when garlic powder was administered
concurrently, suggesting that garlic components were capable of
inducing CYP3A activity.<sup><a href="#R17" rid="R17" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211936">17</a></sup> Conversely, Markowitz et al. found
no significant effect of garlic powder on the pharmacokinetics of
orally administered midazolam, a recognized CYP3A4/5
substrate.<sup><a href="#R18" rid="R18" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211981">18</a></sup> In a similar vein milk thistle
appeared to have no effect on the pharmacokinetics of indinavir, a
substrate for CYP3A4 and P-gp;<sup><a href="#R19" rid="R19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211978">19</a></sup><sup>–</sup><sup><a href="#R21" rid=
"R21" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211948">21</a></sup> however, its effect on
metronidazole, another putative CYP3A/P-gp substrate, suggested
significant induction of these proteins.<sup><a href="#R22" rid=
"R22" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211921">22</a></sup> To complicate matters further is the
significant underreporting of both herb-drug interactions and
adverse events associated with dietary supplements.<sup><a href=
"#R23" rid="R23" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211963">23</a></sup><sup>–</sup><sup><a href="#R25" rid=
"R25" class=" bibr popnode">25</a></sup> Taken together, these
issues highlight the need for more clinical investigations into the
interaction potential of botanical supplements in vivo. Such
studies are particularly desirable for drugs metabolized via
CYP3A-mediated pathways.</p>
<p id="P4">Two popular botanicals, often taken with conventional
medications, that may pose a risk for CYP3A-mediated herb-drug
interactions, include milk thistle (<em>Silybum marianum</em>) and
black cohosh (<em>Cimicifuga racemosa</em>). Milk thistle, promoted
for its hepatoprotective properties,<sup><a href="#R26" rid="R26"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211903">26</a></sup> ranks among the top-selling
botanical supplements in the United States.<sup><a href="#R1" rid=
"R1" class=" bibr popnode">1</a></sup> The purported “active”
phytochemicals present in milk thistle are a series of
flavanolignans, known collectively as “silymarin,” which include
silibinin A, silibinin B, silidianin, silichristin, and taxifolin.
Recent in vitro studies indicate that both silymarin and individual
flavanolignans may function as substrates and/or inhibitors of
human CYP3A4.<sup><a href="#R27" rid="R27" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211911">27</a></sup><sup>–</sup><sup><a href="#R30" rid=
"R30" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211902">30</a></sup> However, as mentioned above,
clinical studies with milk thistle have produced mixed results
regarding its ability to modulate CYP3A4/P-gp in vivo.<sup><a href=
"#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211907">19</a></sup><sup>–</sup><sup><a href="#R22" rid=
"R22" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211915">22</a></sup></p>
<p id="P5" class="p">Black cohosh is a popular alternative therapy
among women for treating menopausal symptoms,<sup><a href="#R31"
rid="R31" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211970">31</a></sup> and recent in vitro studies suggest
that triterpene glycosides present in black cohosh can inhibit
CYP3A4 activity.<sup><a href="#R32" rid="R32" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211939">32</a></sup> To date, only one clinical study has
addressed the drug interaction potential of black cohosh. Gurley et
al. demonstrated that 28 days of black cohosh supplementation,
failed to produce significant changes in phenotypic markers of
CYP1A2, CYP2D6, CY2E1, and CYP3A4 activity among healthy
volunteers, implying a low interaction potential for this
supplement.<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211975">12</a></sup> While the use of phenotypic
metabolic ratios appears to be a suitable method for simultaneously
evaluating multiple CYPs and botanical supplements, a limitation of
the approach lies in its ability to only provide estimates of CYP
probe drug clearance.<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211952">12</a></sup><sup>–</sup><sup><a href="#R14" rid=
"R14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211971">14</a></sup><sup>,</sup><sup><a href="#R33" rid=
"R33" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211924">33</a></sup> For probe drugs like caffeine
(CYP1A2 probe), debrisoquine (CYP2D6 probe), and chlorzoxazone
(CYP2E1 probe), single-time point phenotypic metabolic ratios
appear to be adequate predictors of drug metabolism.<sup><a href=
"#R34" rid="R34" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211965">34</a></sup><sup>–</sup><sup><a href="#R36" rid=
"R36" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211955">36</a></sup> However, for midazolam (CYP3A4
probe) there is some debate about the utility of using one-hour
1-hydroxymidazolam/midazolam ratios to predict midazolam
clearance.<sup><a href="#R37" rid="R37" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211972">37</a></sup><sup>,</sup><sup><a href="#R38" rid=
"R38" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211937">38</a></sup> In this report we describe, for the
first time, the effects of milk thistle and black cohosh
supplementation on the pharmacokinetics of midazolam, a recognized
CYP3A4 substrate. In addition, we compare the effects of milk
thistle and black cohosh to those of rifampin, an inducer of CYP3A4
expression,<sup><a href="#R39" rid="R39" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211968">39</a></sup> and clarithromycin, an inhibitor of
CYP3A4 activity,<sup><a href="#R40" rid="R40" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211906">40</a></sup> as a means of gauging the clinical
relevancy of supplement-mediated interactions.</p>
</div>
<div id="S1" class="tsec sec">
<h2 class="head no_bottom_margin" id="S1title">Methods</h2>
<div id="S2" class="sec sec-first">
<h3>Study subjects</h3>
<p id="P6" class="p p-first-last">The University of Arkansas for
Medical Sciences Human Research Advisory Committee (Little Rock,
AR) approved this study protocol and all participants provided
written informed consent before commencing the study. Nineteen
young adults (9 females) (age, mean ±SD = 28 ± 6 years; weight,
76.5 ± 16.4 kg) participated in the study and all subjects were in
good health as indicated by medical history, routine physical
examination, electrocardiography, and clinical laboratory testing.
All subjects were nonsmokers, ate a normal diet, were not users of
botanical dietary supplements, and were not taking prescription or
nonprescription medications. All female subjects had a negative
pregnancy test at baseline. All subjects were instructed to abstain
from alcohol, caffeine, fruit juices, cruciferous vegetables, and
charbroiled meat throughout each two-week phase of the study.
Adherence to these restrictions was further emphasized five days
before midazolam administration. Subjects were also instructed to
refrain from taking prescription and nonprescription medications
during supplementation periods, and any medication use during this
time was documented. Documentation of compliance to these
restrictions was achieved through the use of a food/medication
diary.</p>
</div>
<div id="S3" class="sec">
<h3>Supplements and supplementation/medication regimens</h3>
<p id="P7" class="p p-first-last">The effect of milk thistle, black
cohosh, rifampin and clarithromycin on midazolam pharmacokinetics
was evaluated individually on four separate occasions in each
subject. This was an open-label study randomized for
supplementation/medication sequence. (“Supplementation/medication”
refers either to milk thistle, black cohosh, rifampin, or
clarithromycin.) Each supplementation phase (milk thistle or black
cohosh) lasted 14 days while each medication phase (rifampin or
clarithromycin) was of 7 days duration. Each
supplementation/medication phase was followed by a 30-day washout
period. This randomly assigned sequence of
supplementation/medication followed by washout was repeated until
each subject had received all four products. Single lots of milk
thistle (lot # 41678) and black cohosh (lot #41924) were purchased
from the same vendor (Enzymatic Therapy, Inc. Green Bay, WI.).
(Enzymatic Therapy Inc. is a leader in the botanical supplement
industry for providing products of high quality and consistency.)
Rifampin (Rifadin<sup>®</sup>, Aventis Pharmaceuticals, Kansas
City, MO.) and clarithromycin (Biaxin<sup>®</sup>, Abbott
Laboratories, North Chicago, IL) were utilized as positive controls
for CYP3A induction and inhibition, respectively. Product labels
were followed regarding the administration of milk thistle (300 mg,
three times daily, standardized to contain 80% silymarin); black
cohosh extract (40 mg, twice daily, standardized to 2.5% triterpene
glycosides); rifampin (300 mg, twice daily); and clarithromycin
(500 mg, twice daily). Telephone and electronic mail reminders were
used to facilitate compliance, while pill counts and
supplementation usage records, were used to verify compliance.</p>
</div>
<div id="S4" class="sec">
<h3>Midazolam administration</h3>
<p id="P8" class="p p-first-last">Following an overnight fast,
subjects reported to the University of Arkansas for Medical
Sciences General Clinical Research Center for midazolam
administration and blood sampling. Prior to midazolam
administration subjects were weighed and questioned about their
adherence to the dietary and medication restrictions. Female
subjects were administered pregnancy tests and only those with
negative test results were allowed to participate. Following the
placement of a 20 gauge, indwelling catheter into a peripheral vein
of the forearm, an oral dose of midazolam (8 mg, Bedford
Laboratories, Bedford, OH) was administered with 240 ml of water.
Throughout the study, midazolam doses were administered 24 hours
before the start of each supplementation/medication phase
(baseline) and again on the last day of each phase. Serial blood
samples were obtained before and at 0.25, 0.50, 0.75, 1, 1.5, 2, 3,
4, 5, and 6 hours after midazolam administration. Blood samples
were allowed to clot for 30 minutes then centrifuged at 2500 rpm.
Serum was removed, placed in 3mL cryovials and stored at −70°C
until analysis. Each subject’s blood pressure, heart rate, and
respiration rate was monitored at 0.5, 1, and 2 hours
post-midazolam administration. Four hours after dosing, subjects
received identical meals consisting of a turkey sandwich, potato
chips, carrot sticks, and water.</p>
</div>
<div id="S5" class="sec">
<h3>Determination of midazolam (MDZ) and 1′-hydroxymidazolam (HMDZ)
serum concentrations</h3>
<p id="P9" class="p p-first">Standard solutions of MDZ and HMDZ
(Sigma, St Louis, MO) were prepared in methanol to give stock
solutions of 1.0 μg/mL and were stored at −20°C until use. The
internal standard, MDZ-[<sup>15</sup>N<sub>3</sub>], (a gift from
Roche Laboratories, Nutley, NJ) was prepared to yield a stock
solution of 0.2 ng/mL in methanol. Working standards were prepared
daily in drug-free serum from the stock solution to yield
concentrations of 250, 100, 50, 25, 10, 5.0, 2.50, 1.0, 0.5, 0.25
and 0.1 ng/mL.</p>
<p id="P10">500 μL of 0.2M sodium acetate (pH 4.75) was added to
each 250 μL serum aliquot. 250 μL of ice-cold β-glucuronidase
(Sigma, St. Louis, MO) were then added and the sample gently
agitated. Samples were incubated at 37°C for 2.5 hours. After
incubation, 2 mL of 0.1% H<sub>3</sub>PO<sub>4</sub> was added
along with 50 μL of the internal standard
(MDZ-[<sup>15</sup>N<sub>3</sub>]) and samples vortex-mixed for 30
seconds. A Strata X-C solid phase extraction (SPE) column
(Phenomenex, Torrance, CA 90501) was used to extract MDZ and HMDZ
from serum. SPE columns were preconditioned with methanol/water.
Serum samples were then loaded onto SPE columns and washed with 2
mL of 0.1% H<sub>3</sub>PO<sub>4</sub> in 50:50
methanol:acetonitrile followed by 1 mL of 50:50
methanol:acetonitrile. MDZ and HMDZ were eluted by gravity flow
using 3 mL 6% ammonia in 50:50 methanol:acetonitrile. Eluents were
dried under nitrogen and reconstituted in 75 μL LC/MS mobile phase
A (30% acetonitrile, 5mM ammonium formate pH 3.0). Samples were
then transferred to microcentrifuge tubes and centrifuged at 13,200
rpm.</p>
<p id="P11">Using a Model 10Avp modular high performance liquid
chromatography (HPLC) system (Shimadzu Corp., Columbia, MD), 10 μL
aliquots were injected onto a 10 × 0.2 cm Gemini 5om C18 column
(Phenomenex, Torrance, CA). MDZ and HMDZ were eluted at a flow of
0.2 mL/min using a 4-min. linear gradient from 30% to 80%
acetonitrile:ammonium formate (5 mM pH 3.0). Analytes were
converted to gas-phase ions in a TurboIon Spray™ heated
electrospray ionization (ESI) source (MDS Sciex, Concord, Ontario,
Canada) operated at +4,400 volts and 425°C. Ions were resolved and
detected in an API3000 triple-quadrupole mass spectrometer (MDS
Sciex, Concord, Ontario, Canada) by multiple reaction monitoring.
MDZ and HMDZ serum concentrations were quantified by a comparison
of the ratio of their peak areas to that of the internal control,
MDZ-[<sup>15</sup>N<sub>3</sub>].</p>
<p id="P12" class="p p-last">Validation studies found that standard
curves were linear over the range of 250 to 0.1 ng/mL and yielded
correlation coefficients &gt; 0.995. The limit of quantitation was
0.1 ng/mL and the limit of detection 0.02 ng/mL. Mean recoveries of
MDZ and HMDZ were 92% and 85%, respectively. Relative standard
deviations for interday accuracy and precision assessments for
quality control standards at 120, 20, and 1.5 ng/mL were &lt;
10%.</p>
</div>
<div id="S6" class="sec">
<h3>Supplement analysis</h3>
<p id="P13" class="p p-first">The phytochemical content of each
supplement was independently analyzed for specific “marker
compounds” by HPLC. Analytical standards of the flavanolignans
taxifolin, silychristin, silydianin, silibinin A, and silibinin B
were purchased from ChromaDex, Inc. (Santa Ana, CA, USA). Standard
solutions of each flavanolignan were prepared in methanol covering
a range of 0.01–1 μg/mL and used for quantitative purposes.
Flavanolignan content of milk thistle was quantitated using a
previously published method.<sup><a href="#R41" rid="R41" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_311359068">41</a></sup> Briefly, contents of six milk
thistle capsules were placed in individual brown glass bottles and
dissolved in 75 mL of ethanol. The contents of each vessel were
agitated at 75 rpm for 4 hours at 60°C. One milliliter aliquots
were removed, evaporated under nitrogen, and redissolved in 1 mL
methanol. 10 μL were injected onto a Symmetry C18 column (150 mm ×
4.6 mm, 5μm) (Waters Corp., Milford, MA, USA) using a Waters
Alliance 2690 component HPLC system (Waters Corp., Milford, MA,
USA). A gradient elution using a mobile phase of methanol:water
(20:80, designated Solvent A and 80:20, designated Solvent B) was
used to separate the flavanolignans. A mixture of 85:15 (Solvent
A:B) was initiated for 5 minutes at a flow of 0.75 ml/min, followed
by a linear gradient over 15 minutes to achieve a mixture of 45:55
(Solvent A:B) which was held constant for an additional 20 minutes.
The gradient was then ramped down linearly over 10 minutes to the
original concentration (85:15, A:B). Column eluent was monitored by
a Model 996 photodiode array detector (Waters Corp., Milford, MA)
at a wavelength of 290nm. Retention times for taxifolin,
silichristin, silidianin, silibinin A, and silibinin B were 9.6,
16.5, 18.8, 23.7 and 24.7 minutes, respectively. The lower limit of
quantitation for each analyte was 0.01 μg/mL. The interday accuracy
and precision for silymarin components at 0.05, 0.1, and 0.5 μg/mL
was &lt; 8%.</p>
<p id="P14" class="p p-last">Black cohosh was analyzed for
triterpene glycosides (cimiracemosides, cimicifugoside,
27-deoxyactein, and actein) (Chromadex Inc., Santa Ana, CA, USA)
using reversed phase HPLC with evaporative light scattering
detection as described previously.<sup><a href="#R42" rid="R42"
class=" bibr popnode">42</a></sup> Standard curves for each
standard were linear over the range of 10 to 400 μg/mL. The limit
of quantitation for cimiracemoside (the least prevalent component)
was 10 μg/mL. Extraction recoveries exceeded 95% and relative
standard deviations for interday accuracy and precision assessments
were &lt; 5%.</p>
</div>
<div id="S7" class="sec">
<h3>Pharmacokinetic analysis and phenotype assessment</h3>
<p id="P15" class="p p-first">MDZ pharmacokinetic parameters were
determined using standard noncompartmental methods with the
computer program WinNonlin (version 2.1; Pharsight, Mountain View,
CA, USA). Area under the serum concentration-time curves from zero
to 6 hours (AUC<sub>(0–6)</sub>) were determined by use of the
trapezoidal rule. The terminal elimination rate constant
(k<sub>e</sub>) was calculated using the slope of the log-linear
regression of the terminal elimination phase. Area under the serum
concentration versus time curve from zero to infinity
(AUC<sub>0–∞</sub>) was calculated using the log-linear trapezoidal
rule up to the last measured time concentration (C<sub>last</sub>)
with extrapolation to infinity using
C<sub>last</sub>/k<sub>e</sub>. The elimination half-life was
calculated as 0.693/k<sub>e</sub>. The apparent oral clearance of
midazolam (Cl/F) was calculated as dose/AUC<sub>0–∞</sub>. Peak MDZ
concentrations (C<sub>max</sub>) and the times when they occurred
(T<sub>max</sub>) were derived directly from the data.</p>
<p id="P16" class="p p-last">The justification of specified time
points for obtaining metabolite/parent serum ratios to estimate
probe drug clearance has been previously addressed.<sup><a href=
"#R13" rid="R13" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211947">13</a></sup> Serum ratios of HMDZ/MDZ determined
one hour after dosing were used to estimate CYP3A activity.
Differences in pre- and post-supplementation/medication HMDZ/MDZ
ratios obtained one hour after MDZ dosing were used to estimate the
effects of rifampin, clarithromycin, milk thistle, and black cohosh
on CYP3A phenotype.</p>
</div>
<div id="S8" class="sec">
<h3>Disintegration tests</h3>
<p id="P17" class="p p-first-last">An absence of botanical-mediated
effects on midazolam pharmacokinetics could stem from products
exhibiting poor disintegration and/or dissolution characteristics.
To address this concern, each product was subjected to
disintegration testing as outlined in the United States
Pharmacopeia 28.<sup><a href="#R43" rid="R43" class=
" bibr popnode">43</a></sup> The disintegration apparatus consisted
of a basket-rack assembly operated at 29–32 cycles per minute with
0.1 N HCl (37°C) as the immersion solution. One dosage unit
(uncoated tablet or soft gel capsule) of each supplement was placed
into each of the six basket assembly tubes. The time required for
the complete disintegration of six dosage units was determined.
This process was repeated with an additional six dosage units to
assure accuracy. Since there are no specifications for the
disintegration time of the botanical supplements used in this
study, the mean of six individual dosage units was taken as the
disintegration time for that particular product. A product was
considered completely disintegrated if the entire residue passed
through the mesh screen of the test apparatus, except for capsule
shell fragments, or if the remaining soft mass exhibited no
palpably firm core.</p>
</div>
<div id="S9" class="sec sec-last">
<h3>Statistical Analysis</h3>
<p id="P18" class="p p-first">A repeated measures ANOVA model was
fit for each pharmacokinetic parameter using SAS Proc Mixed
software (SAS Institute, Inc. Cary, N.C., USA). Since pre-and
post-supplementation/medication pharmacokinetic parameters were
determined in each subject for all four of the study phases, a
covariance structure existed for measurements within subjects. Sex,
supplement/medication, and supplement/medication-by-sex terms were
estimated for each parameter using a Huynh-Feldt covariance
structure fit. If supplement/medication-by-sex interaction terms
for a specific parameter measure were significant at the 5% level,
the focus of the post-supplementation/medication minus
pre-supplementation/medcation response was assessed according to
sex. If the supplement/medication-by-sex interaction was not
statistically significant, responses for both sexes were
combined.</p>
<p id="P19" class="p p-last">An identical approach was taken to
evaluate the effects of the supplementation/medication scheme on
1-hour HMDZ/MDZ ratios. Additionally, a power analysis was
performed to estimate the ability to detect significant post- minus
pre-supplementation/medication effects. All four models obtained at
least 80% power at the 5% level of significance to detect a Cohen
effect size of 1.32 to 1.50 standard deviation units.<sup><a href=
"#R44" rid="R44" class=" bibr popnode">44</a></sup> A Pearson’s
correlation analysis for 1-hour HMDZ/MDZ serum ratios and MDZ oral
clearance was also performed using SAS Proc Corr software (SAS
Institute, Inc. Cary, N.C., USA).</p>
</div>
</div>
<div id="S10" class="tsec sec">
<h2 class="head no_bottom_margin" id="S10title">RESULTS</h2>
<p id="P20" class="p p-first">All nineteen subjects completed each
phase of the study. Neither spontaneous reports from study
participants or their responses to questions asked by study nurses
regarding supplement/medication usage revealed any serious adverse
events. Nausea, indigestion, and complaints of a metallic taste
were frequently noted during clarithromycin phases. Mild
indigestion and reddish discoloration of the urine were common
conditions reported with rifampin use. Three subjects noted an
increase in headaches while taking milk thistle and one subject
associated black cohosh with the onset of “vivid dreams”. No
clinically significant changes in blood pressure, heart rate, or
respiratory rate were observed after MDZ administration.
Examination of pill counts and food/medication diaries revealed no
significant deviations from the study protocol.</p>
<p id="P21">During each pre-supplementation/medication phase,
subjects slept for approximately 1–2 hours after receiving MDZ.
Milk thistle and black cohosh had no noticeable effect on the
duration of MDZ-induced sleep. After rifampin, however, most
subjects either did not sleep or their sleep time was less than 0.5
hours. Clarithromycin increased the average sleep time for all
subjects to 3–4 hours.</p>
<p id="P22">The effects of clarithromycin, rifampin, milk thistle,
and black cohosh on serum MDZ concentration versus time profiles
are depicted in <a href="/pmc/articles/PMC1865122/figure/F1/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure
1</span></a>. Supplement/medication effects on MDZ pharmacokinetics
are presented in <a href="/pmc/articles/PMC1865122/table/T1/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"T1" rid-ob="ob-T1" co-legend-rid=""><span>Table I</span></a>. No
statistical differences were observed for MDZ pharmacokinetic
parameters at the beginning of each supplementation/medication
phase (baseline) (<a href="/pmc/articles/PMC1865122/table/T1/"
target="true" class="fig-table-link table figpopup" rid-figpopup=
"T1" rid-ob="ob-T1" co-legend-rid=""><span>Table I</span></a>).
Statistically significant increases (p &lt; 0.001) in MDZ
AUC<sub>(0–∞)</sub>, C<sub>max</sub>, and elimination half-life
were observed after 7 days of clarithromycin ingestion (<a href=
"/pmc/articles/PMC1865122/figure/F1/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1"
co-legend-rid="lgnd_F1"><span>Figure. 1</span></a>; <a href=
"/pmc/articles/PMC1865122/table/T1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1"
co-legend-rid=""><span>Table I</span></a>). Clarithromycin also
decreased MDZ apparent oral clearance by 88% (1.32 ± 0.34 vs. 0.16
± 0.07 L/hr/kg)(p &lt; 0.001; <a href=
"/pmc/articles/PMC1865122/table/T1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1"
co-legend-rid=""><span>Table I</span></a>). Statistically
significant reductions (p &lt; 0.001) in MDZ AUC<sub>(0–∞)</sub>,
C<sub>max</sub>, and elimination half-life were noted following
rifampin administration (<a href=
"/pmc/articles/PMC1865122/figure/F1/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1"
co-legend-rid="lgnd_F1"><span>Figure 1</span></a>; <a href=
"/pmc/articles/PMC1865122/table/T1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1"
co-legend-rid=""><span>Table I</span></a>). Rifampin increased MDZ
apparent oral clearance by more than 20 fold (1.44 ± 0.37 vs. 29.6
± 15.2 L/hr/kg)(p &lt; 0.001; <a href=
"/pmc/articles/PMC1865122/table/T1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1"
co-legend-rid=""><span>Table I</span></a>). A statistically
significant reduction in T<sub>max</sub> was also observed
following rifampin (p &lt; 0.05; <a href=
"/pmc/articles/PMC1865122/table/T1/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1"
co-legend-rid=""><span>Table I</span></a>). In contrast to rifampin
and clarithromycin, no significant changes in MDZ pharmacokinetics
were observed as a result of milk thistle or black cohosh
supplementation (<a href="/pmc/articles/PMC1865122/figure/F1/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure
1</span></a>; <a href="/pmc/articles/PMC1865122/table/T1/" target=
"true" class="fig-table-link table figpopup" rid-figpopup="T1"
rid-ob="ob-T1" co-legend-rid=""><span>Table I</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="F1"
co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1865122/figure/F1/" target="figure" rid-figpopup=
"F1" rid-ob="ob-F1"><img src=
"/pmc/articles/PMC1865122/bin/nihms20441f1.gif" class="small-thumb"
alt="Figure 1" title="Figure 1" src-large=
"/pmc/articles/PMC1865122/bin/nihms20441f1.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_F1">
<div><a class="figpopup" href="/pmc/articles/PMC1865122/figure/F1/"
target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div>
<!--caption a4-->
<div><span>Midazolam concentration-time profiles before and after
clarithromycin. rifampin, milk thistle and black cohosh. Black
squares = baseline values; gray circles =
post-supplementation/medication values. Error bars = standard
deviations.</span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"T1"><a href="/pmc/articles/PMC1865122/table/T1/" target="table"
rid-ob="ob-T1" rid-figpopup="T1" class=
"table img_link icnblk_img figpopup"><img alt="Table I" title=
"Table I" class="small-thumb" src=
"/pmc/articles/PMC1865122/table/T1/?report=thumb" src-large=
"/pmc/articles/PMC1865122/table/T1/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href="/pmc/articles/PMC1865122/table/T1/"
target="table" rid-figpopup="T1" rid-ob="ob-T1">Table I</a></div>
<!--caption a4-->
<div><span>Midazolam pharmacokinetic parameters before and after
supplementation/drug phases (mean ± s.d.)</span></div>
</div>
</div>
<p id="P23">A significant sex-related difference in baseline (e.g.
pre-supplementation/medication) oral MDZ clearance was observed.
The oral clearance of MDZ was significantly greater in female
subjects (1.61 ± 0.49 versus 1.04 ± 0.30 L/hr/kg; p &lt; 0.001)
than in males. However, no sex-related differences in the extent of
CYP3A induction (i.e., change in pre- versus post-rifampin CL/F/kg)
or inhibition (i.e. change in pre- versus post-clarithromycin
Cl/F/kg) were observed.</p>
<p id="P24">Comparisons of 1-hour HMDZ/MDZ serum concentration
ratios before and after supplementation/medication mirrored the
effects observed for MDZ concentration-time profiles (<a href=
"/pmc/articles/PMC1865122/figure/F2/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="F2" rid-ob="ob-F2"
co-legend-rid="lgnd_F2"><span>Figure 2</span></a>; <a href=
"/pmc/articles/PMC1865122/table/T2/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2"
co-legend-rid=""><span>Table II</span></a>). Like that observed for
baseline values of MDZ oral clearance, no statistically significant
differences occurred among mean values for 1-hour HMDZ/MDZ ratios
at baseline (<a href="/pmc/articles/PMC1865122/table/T2/" target=
"true" class="fig-table-link table figpopup" rid-figpopup="T2"
rid-ob="ob-T2" co-legend-rid=""><span>Table II</span></a>). Again,
as with MDZ oral clearance, a sex-related difference was noted for
mean MDZ phenotype assessments. At each baseline determination,
mean values for female 1-hour HMDZ/MDZ ratios were significantly
greater (4.12 ± 1.3 versus 2.84 ± 0.82; p &lt; 0.001) than those
for males; however, no sex-related effect with regard to extent of
change in MDZ phenotypes was noted after each treatment phase. Mean
post-rifampin 1-hour HMDZ/MDZ serum ratios were significantly
greater than pre-dose values indicating an induction of CYP3A
activity (<a href="/pmc/articles/PMC1865122/figure/F2/" target=
"figure" class="fig-table-link fig figpopup" rid-figpopup="F2"
rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2A</span></a>),
while the opposite was true for clarithromycin treatment signifying
CYP3A inhibition (<a href="/pmc/articles/PMC1865122/figure/F2/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure
2B</span></a>). No significant changes in mean 1-hour HMDZ/MDZ
serum ratios were noted after 14-day courses of either milk thistle
or black cohosh (<a href="/pmc/articles/PMC1865122/figure/F2/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figures
2C</span></a>, <a href="/pmc/articles/PMC1865122/figure/F2/"
target="figure" class="fig-table-link fig figpopup" rid-figpopup=
"F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span style=
"position: relative;text-decoration:none;">​<span class=
"figpopup-sensitive-area" style=
"left: -0.5em;">,2D),</span></span><span>2D</span></a>), suggesting
that these supplements are not potent modulators of CYP3A in vivo.
Correlation analysis revealed a significant positive correlation
between 1-hour HMDZ/MDZ ratios and CL/F/kg (r<sup><a href="#R2"
rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211926">2</a></sup> = 0.82, p &lt; 0.001; <a href=
"/pmc/articles/PMC1865122/figure/F3/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3"
co-legend-rid="lgnd_F3"><span>Figure 3</span></a>).</p>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="F2"
co-legend-rid="lgnd_F2"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1865122/figure/F2/" target="figure" rid-figpopup=
"F2" rid-ob="ob-F2"><img src=
"/pmc/articles/PMC1865122/bin/nihms20441f2.gif" class="small-thumb"
alt="Figure 2" title="Figure 2" src-large=
"/pmc/articles/PMC1865122/bin/nihms20441f2.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_F2">
<div><a class="figpopup" href="/pmc/articles/PMC1865122/figure/F2/"
target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div>
<!--caption a4-->
<div><span>Comparison of pre- and post-supplementation phenotypic
ratios (1-hydroxymidazolam/midazolam) for CYP3A4. (A) Rifampin, (B)
Clarithromycin, (C) Milk thistle, (D) Black cohosh. Gray circles =
individual values; Black circles = group means. Asterisks =
statistically</span> <strong>...</strong></div>
</div>
</div>
<!--fig ft0--><!--fig mode=article f1-->
<div class="fig iconblock ten_col whole_rhythm clearfix" id="F3"
co-legend-rid="lgnd_F3"><a class="icnblk_img figpopup" href=
"/pmc/articles/PMC1865122/figure/F3/" target="figure" rid-figpopup=
"F3" rid-ob="ob-F3"><img src=
"/pmc/articles/PMC1865122/bin/nihms20441f3.gif" class="small-thumb"
alt="Figure 3" title="Figure 3" src-large=
"/pmc/articles/PMC1865122/bin/nihms20441f3.jpg" /></a>
<div class="icnblk_cntnt" id="lgnd_F3">
<div><a class="figpopup" href="/pmc/articles/PMC1865122/figure/F3/"
target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div>
<!--caption a4-->
<div><span>Plot of 1-hour 1′-hydroxymidazolam/midazolam phenotypic
ratios versus midazolam oral clearance (CL/F/kg).</span></div>
</div>
</div>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"T2"><a href="/pmc/articles/PMC1865122/table/T2/" target="table"
rid-ob="ob-T2" rid-figpopup="T2" class=
"table img_link icnblk_img figpopup"><img alt="Table II" title=
"Table II" class="small-thumb" src=
"/pmc/articles/PMC1865122/table/T2/?report=thumb" src-large=
"/pmc/articles/PMC1865122/table/T2/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href="/pmc/articles/PMC1865122/table/T2/"
target="table" rid-figpopup="T2" rid-ob="ob-T2">Table II</a></div>
<!--caption a4-->
<div><span>Pre- and Postsupplementation/medication 1-hour
Phenotypic Ratios</span></div>
</div>
</div>
<p id="P25" class="p p-last">Results of phytochemical analyses and
disintegration testing for milk thistle and black cohosh
formulations are presented in <a href=
"/pmc/articles/PMC1865122/table/T3/" target="true" class=
"fig-table-link table figpopup" rid-figpopup="T3" rid-ob="ob-T3"
co-legend-rid=""><span>Table III</span></a>. Based on these
findings, subjects ingested approximately 440 mg of silymarin and
3.0 mg of triterpene glycosides on a daily basis. In addition, both
dosage forms disintegrated in less than 15 minutes.</p>
<!--table ft1--><!--table-wrap mode=article t1-->
<div class="table-wrap iconblock ten_col whole_rhythm clearfix" id=
"T3"><a href="/pmc/articles/PMC1865122/table/T3/" target="table"
rid-ob="ob-T3" rid-figpopup="T3" class=
"table img_link icnblk_img figpopup"><img alt="Table III" title=
"Table III" class="small-thumb" src=
"/pmc/articles/PMC1865122/table/T3/?report=thumb" src-large=
"/pmc/articles/PMC1865122/table/T3/?report=previmg" /></a>
<div class="icnblk_cntnt">
<div><a class="figpopup" href="/pmc/articles/PMC1865122/table/T3/"
target="table" rid-figpopup="T3" rid-ob="ob-T3">Table III</a></div>
<!--caption a4-->
<div><span>Phytochemical analysis and disintegration times for
botanical dosage forms.</span></div>
</div>
</div>
</div>
<div id="S11" class="tsec sec">
<h2 class="head no_bottom_margin" id="S11title">DISCUSSION</h2>
<p id="P26" class="p p-first">The present findings suggest that
phytochemical components in the milk thistle and black cohosh
formulations investigated in this study did not significantly
affect the pharmacokinetics of MDZ in humans, and therefore are not
likely to pose a significant interaction risk with other CYP3A
substrates. This interpretation is bolstered by the significant
changes in MDZ pharmacokinetics observed following the
administration of clarithromycin, a known CYP3A4 inhibitor, and
rifampin, a recognized inducer of CYP3A4 expression. In addition,
our results do not support previous in vitro findings that
silymarin (i.e., silibinin A, silibinin B silidianin, silichristin,
and taxifolin) inhibits CYP3A4 activity, at least not in the
context of the recommended supplementation regimen used in the
study. This discrepancy may stem from the fact that milk thistle
flavanolignans are practically insoluble in water and that in vitro
studies demonstrating an inhibitory effect of silymarin on CYP3A4
activity have utilized solubilizing agents (e.g.,
dimethylsulfoxide<sup><a href="#R27" rid="R27" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211908">27</a></sup><sup>,</sup><sup><a href="#R29" rid=
"R29" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211945">29</a></sup><sup>,</sup><sup><a href="#R30" rid=
"R30" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211918">30</a></sup> or methanol<sup><a href="#R28" rid=
"R28" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211935">28</a></sup>) to facilitate hepatocyte or
microsomal membrane permeability. Depending on the in vitro model
utilized, IC<sub>50</sub> values for individual flavanolignans or
silymarin extract have ranged from 25–250 μM,<sup><a href="#R27"
rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211967">27</a></sup><sup>–</sup><sup><a href="#R30" rid=
"R30" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211929">30</a></sup> with some evidence that silibinin
can act as a mechanism-based inhibitor of CYP3A.<sup><a href="#R26"
rid="R26" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211925">26</a></sup> From the results of the present
study, it would appear that local silymarin concentrations at
intestinal enterocyte membrane interfaces were lower than the
25–250 μM necessary for in vitro inhibition of CYP3A,<sup><a href=
"#R27" rid="R27" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211943">27</a></sup><sup>–</sup><sup><a href="#R30" rid=
"R30" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211964">30</a></sup> and the degree of mechanism-based
inhibition, if any, was not comparable to that observed with
clarithromycin.</p>
<p id="P27">The milk thistle product used in the present study was
formulated with soybean oil, glycerin, and lecithin in a soft
gelatin capsule, and upon disintegration the contents appeared to
remain undissolved. Since flavanolignan serum concentrations were
not measured, any indication as to their in vivo solubility and/or
bioavailability status remains unknown. Nevertheless,
bioavailability and dissolution characteristics for
silymarin-containing products have been shown to vary widely. An
evaluation of nine separate milk thistle products found that the
amount of silibinin released over one hour into an aqueous buffered
solution (pH 7.5, 37°C) ranged from 0–85%;<sup><a href="#R45" rid=
"R45" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211905">45</a></sup> while a comparative bioavailability
study of three silibinin-containing dosage forms found that values
for AUC and C<sub>max</sub> varied among products by factors of 3
and 6, respectively.<sup><a href="#R46" rid="R46" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211913">46</a></sup> Moreover, several studies have
demonstrated that silymarin-containing products exhibit especially
poor bioavailability and drug-release properties when not
formulated with solubility-enhancing agents like
phosphatidylcholine and polyethylene glycol.<sup><a href="#R45"
rid="R45" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211956">45</a></sup><sup>,</sup><sup><a href="#R47" rid=
"R47" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211927">47</a></sup><sup>–</sup><sup><a href="#R49" rid=
"R49" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211949">49</a></sup> The bioavailability and drug-release
characteristics of silymarin is significantly enhanced when
silibinin is complexed with phosphotidylcholine or formulated as
lipid-containing microspheres.<sup><a href="#R50" rid="R50" class=
" bibr popnode">50</a></sup><sup>–</sup><sup><a href="#R53" rid=
"R53" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211901">53</a></sup> Unlike many European products, the
majority of milk thistle supplements sold in the United States do
not appear to incorporate these technologies.<sup><a href="#R52"
rid="R52" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211958">52</a></sup></p>
<p id="P28">With the multitude of supplement brands available on
the market, discrepancies in product content, formulation,
dissolution, and bioavailability can be the bane of any clinical
safety, efficacy, or herb-drug interaction study—a problem not
limited to milk thistle. Formulation differences could explain the
disparity between a recent study performed in India<sup><a href=
"#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211973">22</a></sup> and several conducted in the United
States<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211932">12</a></sup><sup>,</sup><sup><a href="#R19" rid=
"R19" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211974">19</a></sup><sup>–</sup><sup><a href="#R21" rid=
"R21" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211950">21</a></sup> regarding the effects of milk
thistle on the disposition of CYP3A substrates. Rajnarayana et al.
found that 9 days of silymarin administration (Silybon™) increased
the clearance of metronidazole, a substrate of CYP2C9, CYP3A, and
P-gp, by almost 30%.<sup><a href="#R22" rid="R22" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211976">22</a></sup> The authors concluded that induction
of CYP and/or P-gp might have accounted for the observed effects.
Conversely, milk thistle interaction studies conducted in the
United States and Canada found no statistically significant changes
in the pharmacokinetics of indinavir, a CYP3A/P-gp
substrate,<sup><a href="#R19" rid="R19" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211920">19</a></sup><sup>–</sup><sup><a href="#R21" rid=
"R21" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211938">21</a></sup> although slight reductions (8–18%)
in indinavir AUC were noted in each study. Collectively, the above
studies hint at a possible mild inductive effect of silymarin on
CYP3A and/or P-gp. In the only in vitro examination of milk thistle
components on CYP3A induction, Raucy, using a reporter gene assay
for the human pregnane X receptor and promoter regions of CYP3A
transfected in HepG2 cells, found no evidence that silymarin, when
solubilized with dimethylsulfoxide (DMSO), could induce the
enzyme.<sup><a href="#R54" rid="R54" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211944">54</a></sup> Furthermore, in a previous study
utilizing MDZ, we found that 28 days of milk thistle
supplementation had no significant effect on 1-hour HMDZ/MDZ ratios
(a finding confirmed by the current results) implying that
conventional silymarin formulations are devoid of any clinically
relevant CYP3A modulatory effects.<sup><a href="#R12" rid="R12"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211951">12</a></sup> Taken together, our results and
those reported previously suggest that, when compared to potent
inducers and inhibitors of CYP3A, milk thistle flavanolignans pose
no clinically significant risks for pharmacokinetic herb-drug
interactions involving CYP3A substrates.</p>
<p id="P29">Recent in vitro findings demonstrate that, in the
presence of DMSO, black cohosh extracts or individual triterpene
glycosides can inhibit CYP3A.<sup><a href="#R32" rid="R32" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211954">32</a></sup> However, the results reported here,
and earlier,<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211941">12</a></sup> indicate that, when compared to
clarithromycin and rifampin, recommended doses of black cohosh
triterpene glycosides do not affect MDZ disposition and are
therefore not effective modulators of CYP3A in vivo. Whether this
lack of effect is a function of dose, solubility, bioavailability,
or a combination of factors remains to be seen. Like many botanical
supplements, the pharmacokinetic profile of black cohosh’s
constituent phytochemicals has not been adequately investigated.
Only one group has described an attempt at measuring mercapturate
conjugates of black cohosh constituents (fukinolic acid, fukiic
acid, caffeic acid, and cimiracemate B) in the urine of women after
consuming 256 mg of a standardized black cohosh extract, and none
of the target conjugates were detected.<sup><a href="#R55" rid=
"R55" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211912">55</a></sup> This finding alone brings into
question the cellular permeability and bioavailability of these
specific phytochemicals. Accordingly, the available in vivo
evidence would seem to render black cohosh as an unlikely source of
clinically important herb-drug interactions.</p>
<p id="P30">Poor systemic bioavailability of phytochemicals,
however, may not always be associated with a lack of CYP3A
modulation. This is best illustrated with grapefruit juice.
Grapefruit juice, a well recognized mechanism-based inhibitor of
intestinal CYP3A4 produces significant reductions in the oral
clearance of many CYP3A4 substrates, yet the two phytochemicals
primarily responsible for this effect, bergamottin and
6′,7′-dihydroxybergamottin, do not attain measurable concentrations
in the plasma.<sup><a href="#R56" rid="R56" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211957">56</a></sup> From the results of the present
study, however, it would appear that concentrations of specific
milk thistle and black cohosh phytochemicals were insufficient to
elicit any clinically noticeable effects on CYP3A.</p>
<p id="P31">Of particular interest was the close agreement between
MDZ pharmacokinetic parameters described here and those reported
earlier by Gorski et al.<sup><a href="#R39" rid="R39" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211909">39</a></sup><sup>,</sup><sup><a href="#R40" rid=
"R40" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211916">40</a></sup> Like Gorski, we too noted a
sex-related difference in oral MDZ clearance with women exhibiting
higher values than men.<sup><a href="#R40" rid="R40" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211904">40</a></sup> Unlike Gorski, however, we failed to
observe a sex-related effect in the response of CYP3A to induction
by rifampin<sup><a href="#R39" rid="R39" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211899">39</a></sup> or inhibition by
clarithromycin.<sup><a href="#R40" rid="R40" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211942">40</a></sup></p>
<p id="P32">Our findings also support the utility of 1-hour
HMDZ/MDZ ratios as a practical method for identifying herb-drug
interactions that involve CYP3A induction or inhibition.
Previously, this approach had been used to document CYP3A induction
following St. John’s wort supplementation,<sup><a href="#R13" rid=
"R13" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211980">13</a></sup><sup>,</sup><sup><a href="#R14" rid=
"R14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211969">14</a></sup> and its inhibition by
goldenseal.<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211931">12</a></sup> The method also demonstrated that an
absence of change in mean phenotypic ratios following botanical
supplementation could be interpreted as a lack of effect on CYP
activity. Such was the case with <em>Citrus aurantium, Ginkgo
biloba</em>, <em>Panax ginseng,</em> and saw palmetto
extracts<sup><a href="#R13" rid="R13" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211914">13</a></sup><sup>,</sup><sup><a href="#R14" rid=
"R14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211946">14</a></sup><sup>,</sup><sup><a href="#R33" rid=
"R33" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211961">33</a></sup>—the latter three examples being
confirmed by other investigators using more conventional
area-under-the-curve assessments.<sup><a href="#R57" rid="R57"
class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211928">57</a></sup><sup>–</sup><sup><a href="#R59" rid=
"R59" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211953">59</a></sup> The list can now be extended to
include milk thistle and black cohosh. Thus, a range of
herb-mediated effects on CYP activity (e.g. induction, inhibition,
or no effect) can be differentiated with single time-point
phenotypic ratios. It must be emphasized, however, that single-time
point phenotypic ratios simply provide estimates of probe drug
clearance. The utility of these approximations have recently come
under question, with some investigators finding the correlations
unacceptable.<sup><a href="#R38" rid="R38" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211960">38</a></sup> We, however, found that the change,
or lack thereof, in HMDZ/MDZ ratios provided a reasonable
correlation with oral MDZ clearance (<a href=
"/pmc/articles/PMC1865122/figure/F3/" target="figure" class=
"fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3"
co-legend-rid="lgnd_F3"><span>Figure 3</span></a>). Our aim is not
to propose that traditional means of determining MDZ clearance can
be supplanted by metabolic phenotypic ratios; however, we do
believe they provide a less labor-intensive, more subject-friendly
means for evaluating multiple CYP enzymes and multiple botanical
supplements in vivo while using a limited blood-sampling
scheme.<sup><a href="#R12" rid="R12" class=
" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211917">12</a></sup><sup>–</sup><sup><a href="#R14" rid=
"R14" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211959">14</a></sup><sup>,</sup><sup><a href="#R33" rid=
"R33" class=" bibr popnode tag_hotlink tag_tooltip" id=
"__tag_144211934">33</a></sup> In short, single-time point
metabolic phenotypic ratios may serve as a cost-effective in vivo
screening method for assessing potential CYP-mediated herb-drug
interactions. Once identified, candidate herbs may be evaluated
further by using more traditional pharmacokinetic approaches.</p>
<p id="P33" class="p p-last">In conclusion, when compared to the
effects of rifampin and clarithromycin, the specific brand of milk
thistle and black cohosh supplements utilized in this study
produced no significant changes in the disposition of midazolam, a
clinically recognized CYP3A substrate. Accordingly, these two
products appear to pose no clinically significant risk for
CYP3A-mediated herb-drug interactions. However, given the
inter-product variability in phytochemical content, potency, and
formulation among botanical supplements, these results may not
extend to regimens utilizing higher dosages, longer supplementation
periods, or brands with improved dissolution and/or bioavailability
characteristics.</p>
</div>
<div id="__ref-listid763513" class="tsec sec">
<h2 class="head no_bottom_margin" id="__ref-listid763513title">
References</h2>
<div class="ref-list-sec sec" id="reference-list">
<div class="ref-cit-blk half_rhythm" id="R1">1. <span class=
"citation">Committee on the Use of Complementary and Alternative
Medicine by the American Public. <span class=
"ref-journal">Complementary and Alternative Medicine in the United
States.</span> The National Academies Press; Washington, DC:
2005.</span></div>
<div class="ref-cit-blk half_rhythm" id="R2">2. <span class=
"citation">Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell
AA. Recent patterns of medication use in the ambulatory adult
population of the United States. <span><span class=
"ref-journal">JAMA.</span> 2002;<span class=
"ref-vol">287</span>:337–344.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11790213" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R3">3. <span class=
"citation">Brazier NC, Levine MAH. Drug-herb interactions among
commonly used conventional medicines: a compendium for health care
professionals. <span><span class="ref-journal">Am J Ther.</span>
2003;<span class="ref-vol">10</span>:163–169.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12756423" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R4">4. <span class=
"citation">Hu Z, Yang X, Ho PCL, Chan SY, Heng PWS, Chan E, Duan W,
Kph HL, Zhou S. Herb-drug interactions: a literature review.
<span><span class="ref-journal">Drugs.</span> 2005;<span class=
"ref-vol">65</span>:1239–1282.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15916450" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R5">5. <span class=
"citation">Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee
VKK. St. John’s wort, a herbal antidepressant, activates the
steroid X receptor. <span><span class="ref-journal">J
Endocrinol.</span> 2000;<span class=
"ref-vol">166</span>:R11–R16.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10974665" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R6">6. <span class=
"citation">Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM,
Steinert HC, Meier PJ, Fattinger K. St. John’s wort induces
intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
2000;<span class="ref-vol">68</span>:598–604.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11180019" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R7">7. <span class=
"citation">Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi
A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura
A. Different effects of St. John’s wort on the pharmacokinetics of
simvastatin and pravastatin. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 2002;<span class=
"ref-vol">70</span>:518–524.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11753267" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R8">8. <span class=
"citation">Dresser GK, Schwartz UI, Wilkinson GR, Kim RB.
Coordinate induction of both cytochrome P4503A and MDR1 by St.
John’s wort in healthy subjects. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2003;<span class=
"ref-vol">73</span>:41–50.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12545142" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R9">9. <span class=
"citation">Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH,
Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition
of human cytochrome P450-mediated metabolism of marker substrates
by natural products. <span><span class=
"ref-journal">Phytomed.</span> 2003;<span class=
"ref-vol">10</span>:334–342.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12809364" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R10">10. <span class=
"citation">Strandell J, Neil A, Carlin G. An approach to the in
vitro evaluation of potential for cytochrome P450 enzyme inhibition
from herbals and other natural remedies. <span><span class=
"ref-journal">Phytomed.</span> 2004;<span class=
"ref-vol">11</span>:98–104.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15070158" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R11">11. <span class=
"citation">Zou L, Harkey MR, Henderson GL. Effects of herbal
components on cDNA-expressed cytochrome P450 enzyme catalytic
activity. <span><span class="ref-journal">Life Sci.</span>
2002;<span class="ref-vol">71</span>:1579–1589.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12127912" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R12">12. <span class=
"citation">Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry
WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava,
black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1,
and 3A4/5 phenotypes. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 2005;<span class=
"ref-vol">77</span>:415–426.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1894911/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/15900287" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R13">13. <span class=
"citation">Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry
WB, Cui Y, Ang CYW. Cytochrome P450 phenotypic ratios for
predicting herb-drug interactions in humans. <span><span class=
"ref-journal">Clin Pharmacol Ther.</span> 2002;<span class=
"ref-vol">72</span>:276–287.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12235448" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R14">14. <span class=
"citation">Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry
WB, Cui Y, Ang CYW. Clinical assessment of effects of botanical
supplementation on cytochrome P450 phenotypes in the elderly: St.
John’s wort, garlic oil, panax ginseng, and ginkgo biloba.
<span><span class="ref-journal">Drugs Aging.</span>
2005;<span class="ref-vol">22</span>:525–539.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1858666/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/15974642" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R15">15. <span class=
"citation">Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS.
Pharmacogenetics and herb-drug interactions: experience with Ginkgo
biloba and omeprazole. <span><span class=
"ref-journal">Pharmacogenetics.</span> 2004;<span class=
"ref-vol">14</span>:841–850.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15608563" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R16">16. <span class=
"citation">Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK,
Zaheer NA, Desai M, Miller M, Hall SD. The effect of Echinacea
(<em>Echinacea purpurea</em> root) on cytochrome P450 activity in
vivo. <span><span class="ref-journal">Clin Pharmacol Ther.</span>
2004;<span class="ref-vol">75</span>:89–100.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/14749695" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R17">17. <span class=
"citation">Piscitelli SC, Burstein AH, Welden N, Gallicano KD,
Falloon J. The effect of garlic supplements on the pharmacokinetics
of saquinavir. <span><span class="ref-journal">Clin Infect
Dis.</span> 2002;<span class="ref-vol">34</span>:234–238.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/11740713" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R18">18. <span class=
"citation">Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y,
Donovan JL. Effects of garlic (Allium sativum L.) supplementation
on cytochrome P450 2D6 and 3A4 activity in healthy volunteers.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
2003;<span class="ref-vol">74</span>:170–177.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12891227" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R19">19. <span class=
"citation">Piscitelli SC, Formentini E, Burstein AH, Alfaro R,
Jagannatha S, Falloon J. Effect of milk thistle on the
pharmacokinetics of indinavir in healthy volunteers.
<span><span class="ref-journal">Pharmacotherapy.</span>
2002;<span class="ref-vol">22</span>:551–556.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12013352" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R20">20. <span class=
"citation">DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A,
Reichman R, Morse G. Coadministration of milk thistle and indinavir
in healthy subjects. <span><span class=
"ref-journal">Pharmacotherapy.</span> 2003;<span class=
"ref-vol">23</span>:866–870.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12885100" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R21">21. <span class=
"citation">Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis
B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K.
Milk thistle and indinavir: a randomized controlled
pharmacokinetics study and meta analysis. <span><span class=
"ref-journal">Eur J Clin Pharmacol.</span> 2005;<span class=
"ref-vol">61</span>:1–7.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15666173" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R22">22. <span class=
"citation">Rajnarayana K, Reddy MS, Vidyasagar Krishna DR. Study on
the influence of silymarin pretreatment on metabolism and
disposition of metronidazole. <span><span class=
"ref-journal">Arzneim Forsch.</span> 2004;<span class=
"ref-vol">54</span>:109–113.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15038460" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R23">23. <span class=
"citation">Hensrud DD, Engle DD, Scheitel SM. Underreporting the
use of dietary supplements and nonprescription medications among
patients undergoing a periodic health examination.
<span><span class="ref-journal">Mayo Clin Proc.</span>
1999;<span class="ref-vol">74</span>:443–447.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10319072" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R24">24. <span class=
"citation">Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E.
Different standards for reporting ADRs to herbal remedies and
conventional OTC medicines: face-to-face interviews with 515 users
of herbal remedies. <span><span class="ref-journal">Br J Clin
Pharmacol.</span> 1998;<span class=
"ref-vol">45</span>:496–500.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1873549/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/9643624" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R25">25. <span class=
"citation">Yessian MR, Greenleaf JM. <span class=
"ref-journal">Adverse event reporting for dietary supplements: an
inadequate safety valve.</span> Department of Health and Human
Services, Office of Inspector General; Washington DC: 2001.
[accessed 9/14/2005]. <a href="http://www.dhhs.gov/oig/oei" ref=
"reftype=extlink&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal"
target="pmc_ext">www.dhhs.gov/oig/oei</a>.</span></div>
<div class="ref-cit-blk half_rhythm" id="R26">26. <span class=
"citation">Saller R, Meier R, Brignoli R. The use of silymarin in
the treatment of liver diseases. <span><span class=
"ref-journal">Drugs.</span> 2001;<span class=
"ref-vol">61</span>:2035–2063.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11735632" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R27">27. <span class=
"citation">Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg
PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits
major hepatic glucuronosyltransferases. <span><span class=
"ref-journal">Drug Metab Dispos.</span> 2004;<span class=
"ref-vol">32</span>:587–594.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15155549" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R28">28. <span class=
"citation">Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova
J, Simanek V, Anzenbacher P. Effect of silybin and its congeners on
human liver microsomal cytochrome P450 activities.
<span><span class="ref-journal">Phytother Res.</span>
2002;<span class="ref-vol">16</span>:632–638.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12410543" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R29">29. <span class=
"citation">Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S,
Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases
the activity of CYP3A4 and uridine diphosphoglucuronsyl transferse
in human hepatocyte cultures. <span><span class="ref-journal">Drug
Metab Dispos.</span> 2000;<span class=
"ref-vol">28</span>:1270–1273.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/11038151" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R30">30. <span class=
"citation">Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker RH,
Beckurts T, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibinin
on cytochromes P-450 enzymes in human liver microsomes.
<span><span class="ref-journal">Pharmacol Toxicol.</span>
2000;<span class="ref-vol">86</span>:250–256.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10895987" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R31">31. <span class=
"citation">Borrelli F, Izzo AA, Ernst E. Pharmacological effects of
<em>Cimicifuga racemosa</em>. <span><span class="ref-journal">Life
Sci.</span> 2003;<span class="ref-vol">73</span>:1215–1229.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/12850238" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R32">32. <span class=
"citation">Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4
inhibitors from the black cohosh (<em>Cimicifuga racemosa</em>)
<span><span class="ref-journal">eCAM.</span> 2005;<span class=
"ref-vol">2</span>:223–226.</span> <span class=
"nowrap ref pmc">[<a class="int-reflink" href=
"/pmc/articles/PMC1142198/">PMC free article</a>]</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/15937564" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R33">33. <span class=
"citation">Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry
B, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of
botanical supplementation on human cytochrome P450 phenotypes:
<em>Citrus aurantium</em>, <em>Echinacea purpurea</em>, milk
thistle, saw palmetto. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 2004;<span class=
"ref-vol">76</span>:428–440.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15536458" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R34">34. <span class=
"citation">Kivisto KT, Kroemer HK. Use of probe drugs as predictors
of drug metabolism in humans. <span><span class="ref-journal">J
Clin Pharmacol.</span> 1997;<span class=
"ref-vol">37</span>:40S–48S.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9048284" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R35">35. <span class=
"citation">Streetman DS, Bertino JS, Nafziger AN. Phenotyping of
drug metabolizing enzymes in adults: a review of in-vivo cytochrome
P450 phenotyping probes. <span><span class=
"ref-journal">Pharmacogenetics.</span> 2000;<span class=
"ref-vol">10</span>:187–216.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/10803676" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R36">36. <span class=
"citation">Bachman KA. Genotyping and phenotyping the cytochrome
P-450 enzymes. <span><span class="ref-journal">Am J Ther.</span>
2002;<span class="ref-vol">9</span>:309–316.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12115020" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R37">37. <span class=
"citation">Zhu B, Ou-Yang D-S, Cheng Z-N, Huang S-L, Zhou H-H.
Single plasma sampling to predict oral clearance of CYP3A probe
midazolam. <span><span class="ref-journal">Acta Pharmacol
Sin.</span> 2001;<span class="ref-vol">22</span>:634–638.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/11749829" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R38">38. <span class=
"citation">Rogers JF, Nafziger AN, Kashuba ADM, Streetman DS, Rocci
ML, Choo EF, Wilkinson GR, Bertino JS. Single plasma concentrations
of 1′-hydroxymidazolam or the ratio of
1′-hydroxymidazolam:midazolam do not predict midazolam clearance in
healthy subjects. <span><span class="ref-journal">J Clin
Pharmacol.</span> 2002;<span class=
"ref-vol">42</span>:1079–1082.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12362920" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R39">39. <span class=
"citation">Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT,
Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and
rifampin administration on intestinal and hepatic cytochrome P450
3A activity. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2003;<span class="ref-vol">74</span>:275–287.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/12966371" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R40">40. <span class=
"citation">Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA,
O’Mara EM, Hall SD. The contribution of intestinal and hepatic CP3A
to the interaction between midazolam and clarithromycin.
<span><span class="ref-journal">Clin Pharmacol Ther.</span>
1998;<span class="ref-vol">64</span>:133–143.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9728893" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R41">41. <span class=
"citation">Wallace SN, Carrier DJ, Clausen EC. Extraction of
nutraceuticals from milk thistle. <span><span class=
"ref-journal">Appl Biochem Biotech.</span> 2003;<span class=
"ref-vol">105–108</span>:891–903.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12721426" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R42">42. <span class=
"citation">Ganzera M, Bedir E, Khan IA. Separation of
<em>Cimicifuga racemosa</em> triterpene glycosides by evaporative
light scattering detection. <span><span class=
"ref-journal">Chromatographia.</span> 2000;<span class=
"ref-vol">52</span>:301–304.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R43">43. <span class=
"citation"><span class="ref-journal">The Pharmacopeia of the United
States Twenty-eighth Revision, and the National Formulary.</span>
23. United States Pharmacopeial Convention, Inc; Rockville, MD:
2004. Disintegration and dissolution of dietary supplements; pp.
2778–2779.</span></div>
<div class="ref-cit-blk half_rhythm" id="R44">44. <span class=
"citation">Cohen J. <span class="ref-journal">Statistical Power
Analysis for the Behavioral Sciences.</span> 2. Hillsdale (NJ):
Lawrence Erlbaum Associates Publishers; 1988. pp.
19–42.</span></div>
<div class="ref-cit-blk half_rhythm" id="R45">45. <span class=
"citation">Schulz H-U, Schurer M, Krumbiegel G, Wachter W,
Weyhenmeyer R, Seidel G. Investigation of dissolution and
bioequivalence of silymarin products. <span><span class=
"ref-journal">Arzneim-Forsch.</span> 1995;<span class=
"ref-vol">45</span>:61–64.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/7893272" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R46">46. <span class=
"citation">Kim YC, Kim EJ, Lee ED, Kim JH, Jang SW, Kim YG, Kwon
JW, Kim WB, Lee MG. Comparative bioavailability of silibinin in
healthy male volunteers. <span><span class="ref-journal">Int J Clin
Pharmacol Ther.</span> 2003;<span class=
"ref-vol">41</span>:593–596.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/14692709" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R47">47. <span class=
"citation">Schandalik R, Gatti G, Perucca E. Pharmacokinetics of
silybin in bile following administration of silipide and silymarin
in cholecystectomy patients. <span><span class=
"ref-journal">Arzneim-Forsch.</span> 1992;<span class=
"ref-vol">42</span>:964–968.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/1329780" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R48">48. <span class=
"citation">Savio D, Harrasser PC, Basso G. (1998) Softgel capsule
technology as an enhancer device for the absorption of natural
principles in humans: a bioavailability cross-over randomized study
on silybin. <span><span class="ref-journal">Arzneim-Forsch.</span>
1998;<span class="ref-vol">48</span>:1104–1106.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/9850434" target="pmc_ext"
ref="reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R49">49. <span class=
"citation">Li F-Q, Hu J-H. Improvement of the dissolution rate of
silymarin by means of solid dispersions. <span><span class=
"ref-journal">Chem Pharm Bull.</span> 2004;<span class=
"ref-vol">52</span>:972–973.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15304992" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R50">50. <span class=
"citation">Orlando R, Fragasso A, Lampertico M, Marena C. Silybin
kinetics in patients with liver cirrhosis: a comparative study of a
silybin-phosphatidylcholine complex and silymarin.
<span><span class="ref-journal">Med Sci Res.</span>
1990;<span class="ref-vol">18</span>:861–863.</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R51">51. <span class=
"citation">Gatti G, Perucca E. Plasma concentrations of free and
conjugated silybin after oral intake of a
silybin-phosphatidylcholine complex (silipide) in healthy
volunteers. <span><span class="ref-journal">Int J Clin Pharmacol
Ther.</span> 1994;<span class="ref-vol">32</span>:614–617.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/7874377" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R52">52. <span class=
"citation">Kidd P, Head K. A review of the bioavailability and
clinical efficacy of milk thistle phytosome: a
silybin-phosphatidylcholine complex (Siliphos) <span><span class=
"ref-journal">Altern Med Rev.</span> 2005;<span class=
"ref-vol">10</span>:193–203.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/16164374" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R53">53. <span class=
"citation">Abrol S, Trehan A, Katare OP. Formulation,
characterization, and in vitro evaluation of silymarin-loaded lipid
microspheres. <span><span class="ref-journal">Drug Deliv.</span>
2004;<span class="ref-vol">11</span>:185–191.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15204637" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R54">54. <span class=
"citation">Raucy JL. Regualtion of CYP3A4 expression in human
hepatocytes by pharmaceuticals and natural products.
<span><span class="ref-journal">Drug Metab Dispos.</span>
2003;<span class="ref-vol">31</span>:533–539.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12695340" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R55">55. <span class=
"citation">Johnson BM, van Breemen RB. In vitro formation of
quinoid metabolites of the dietary supplement <em>Cimicifuga
racemosa</em> (Black cohosh) <span><span class="ref-journal">Chem
Res Toxicol.</span> 2003;<span class=
"ref-vol">16</span>:838–846.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12870886" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R56">56. <span class=
"citation">Goosen TC, Cillie D, Bailey DG, et al. Bergamottin
contribution to the grapefruit juice-felodipine interaction and
disposition in humans. <span><span class="ref-journal">Clin
Pharmacol Ther.</span> 2004;<span class=
"ref-vol">76</span>:607–617.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/15592332" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R57">57. <span class=
"citation">Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin
KD. Multiple-dose administration of Ginkgo biloba did not affect
cytochrome P-450 2D6 or 3A4 activity in normal volunteers.
<span><span class="ref-journal">J Clin Psychopharmacol.</span>
2003;<span class="ref-vol">23</span>:576–581.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/14624188" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R58">58. <span class=
"citation">Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug
interaction potential of soy extract and Panax ginseng.
<span><span class="ref-journal">J Clin Pharmacol.</span>
2003;<span class="ref-vol">43</span>:643–648.</span> <span class=
"nowrap ref pubmed">[<a href="/pubmed/12817527" target="pmc_ext"
ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
<div class="ref-cit-blk half_rhythm" id="R59">59. <span class=
"citation">Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y,
Wang J-S, Chavin KD. Multiple doses of saw palmetto (Serenoa
repens) did not alter cytochrome P450 2D6 and 3A4 activity in
normal volunteers. <span><span class="ref-journal">Clin Pharmacol
Ther.</span> 2003;<span class="ref-vol">74</span>:536–542.</span>
<span class="nowrap ref pubmed">[<a href="/pubmed/14663456" target=
"pmc_ext" ref=
"reftype=pubmed&amp;article-id=1865122&amp;issue-id=144071&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div>
</div>
</div>
</div>
<!--post-content--></div>
</div>
<!-- Book content --></div>
<div id="rightcolumn" class="four_col col last">
<!-- Custom content above discovery portlets -->
<div class="col6"></div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance">
<div class="try-button"><a href=
"/pmc/articles/PMC1865122/?report=reader"><img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/3838809"
alt="PubReader format: click here to try" /></a></div>
<div class="format-menu">
<h2>Formats:</h2>
<ul>
<li class="selected">Article</li>
<li style="list-style: none">|</li>
<li><a href=
"/pmc/articles/PMC1865122/?report=reader">PubReader</a></li>
<li style="list-style: none">|</li>
<li class="epub-link"><a href="/pmc/articles/PMC1865122/epub/">ePub
(beta)</a></li>
<li style="list-style: none">|</li>
<li><a href="/pmc/articles/PMC1865122/pdf/nihms20441.pdf">PDF
(498K)</a></li>
<li style="list-style: none">|</li>
<li><a href="#" data-citationid="PMC1865122" class=
"citationexporter ctxp">Citation</a></li>
</ul>
</div>
</div>
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi=
"http://www.w3.org/2001/XMLSchema-instance" class="share-buttons">
<h2>Share</h2>
<ul>
<li class="facebook"><a href=
"https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1865122%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047626"
alt="Share on Facebook" /> Facebook</a></li>
<li class="twitter"><a href=
"https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1865122%2F&amp;text=Assessing%20the%20clinical%20significance%20of%20botanical%20supplementation%20on%20human%20cytochrome%20P450%203A%20activity%3A%20Comparison%20of%20a%20milk%20thistle%20and%20black%20cohosh%20product%20to%20rifampin%20and%20clarithromycin">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047627"
alt="Share on Twitter" /> Twitter</a></li>
<li class="gplus"><a href=
"https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1865122%2F">
<img src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/img/4047628"
alt="Share on Google Plus" /> Google+</a></li>
</ul>
</div>
<div id="ajax-portlets" data-pmid="16432272" data-aiid="1865122"
data-aid="1865122" data-iid="144071" data-domainid="319"
data-domain="nihpa" data-accid="PMC1865122" data-md5=
"73b69b64df455b33dc4a59cb470c69c7"></div>
<!-- Custom content below discovery portlets -->
<div class="col7"></div>
</div>
</div>
<!-- Custom content after all -->
<div class="col8"></div>
<div class="col9"></div>
<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js">
</script> <script>
<![CDATA[
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
]]>
</script>
<div id="body-link-poppers"></div>
</div>
<div class="bottom">
<div id="NCBIFooter_dynamic">
<div class="breadcrumbs">You are here: <span id=
"breadcrumb_text"><a href="/guide/">NCBI</a> &gt; <a href=
"http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt;
<a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central
(PMC)</a></span></div>
<a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target=
"_blank" href=
"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-04-01T09:54:11-04:00&amp;Host=ptpmc101">Write
to the Help Desk</a></div>
<div class="footer" id="footer">
<div class="subfooter"></div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/preloaderWidget.js">
</script>
<div id="external-disclaimer" class="offscreen_noflow">External
link. Please review our <a href=
"http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div>
<div id="ncbifooter" class="contact_info">
<div id="footer-contents-right">
<div id="nlm_thumb_logo"><a href="http://www.nlm.nih.gov" title=
"NLM">NLM</a></div>
<div id="nih_thumb_logo"><a href="http://www.nih.gov" title=
"NIH">NIH</a></div>
<div id="hhs_thumb_logo"><a href="http://www.dhhs.gov" title=
"DHHS">DHHS</a></div>
<div id="usagov_thumb_logo"><a href="http://www.usa.gov" title=
"USA.gov">USA.gov</a></div>
</div>
<div id="footer-contents-left"><a href=
"/About/disclaimer.html">Copyright</a> | <a href=
"/About/disclaimer.html#disclaimer">Disclaimer</a> | <a href=
"http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a>
| <a href="/guide/browsers/">Browsers</a> | <a href=
"http://www.nlm.nih.gov/accessibility.html">Accessibility</a> |
<a href="/About/glance/contact_info.html">Contact</a>
<p class="address vcard"><span class="url"><a class=
"fn url newdomain" href="http://www.ncbi.nlm.nih.gov">National
Center for Biotechnology Information</a>,</span> <span class=
"org url"><a href="http://www.nlm.nih.gov/">U.S. National Library
of Medicine</a></span> <span class="adr"><span class=
"street-address">8600 Rockville Pike</span>, <span class=
"locality">Bethesda</span> <span class="region">MD</span>,
<span class="postal-code">20894</span> <span class=
"country-name">USA</span></span></p>
</div>
</div>
<script type="text/javascript" src=
"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1">
</script> <script type="text/javascript" src=
"/portal/portal3rc.fcgi/static/js/hfjs2.js">
</script></div>
</div>
</div>
<!--/.page--></div>
<!--/.wrap--></div>
<!-- /.twelve_col --></div>
<!-- /.grid -->
 <!-- BESelector tab -->
 <noscript><img alt="statistics" src=
"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC1865122/&amp;ncbi_app=pmc" />
</noscript> <!-- usually for JS scripts at page bottom -->
 <!--<component id="PageFixtures" label="styles"></component>-->
 
<!-- 8A1A16CC6FE7D821_0216SID /projects/PMC/PMCViewer@4.35 ptpmc101 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->
 <script type="text/javascript" src=
"//static.pubmed.gov/portal/portal3rc.fcgi/4072591/js/3879255/3728312/3818874/3821238/4064716/4072593/4064449/3921943/4070217/4065628.js"
snapshot="pmc">
</script>
</body>
</html>
